Does Ambetter cover Wegovy? Only some conditions

Centene's marketplace policy for Wegovy gives weight management its own numbered section and then refuses it in one sentence: "Use of Wegovy for the treatment of weight management is a benefit exclusion and will not be authorized." The approval duration field for that section reads "Not applicable." The sentence appears twice, once under Initial Approval Criteria and again under Continued Therapy, so a member already on the drug through another payer has no continuation pathway either. This is a benefit exclusion rather than a clinical denial, which means BMI, comorbidities and documentation do not change the outcome.

Policy CP.PMN.295. Source: Centene Clinical Policy CP.PMN.295, Semaglutide (Wegovy), sections I.B and II.B. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full, all 13 pages). HIM is Centene's abbreviation for health insurance marketplace, the line of business Ambetter is sold under.. Verified August 15, 2026.

The Zepbound policy carries the same construction and the same sentence: "Use of Zepbound for the treatment of weight management is a benefit exclusion and will not be authorized", with an approval duration of "Not applicable", repeated under both Initial Approval Criteria and Continued Therapy. Ambetter has also said this in plain language to members. A member-news notice from Ambetter from Arkansas Health and Wellness dated November 21 2025 is titled GLP-1 Medications: Coverage Exclusions for Weight Loss Treatment and states that Ambetter does not currently cover GLP-1s when prescribed solely for weight management, while noting the drugs stay covered for type 2 diabetes. That notice is scoped to the Arkansas plan.

Policy CP.PMN.298. Source: Clinical Policy: Tirzepatide (Zepbound), Reference Number CP.PMN.298, Effective Date 12.20.24, Last Review Date 02.25, Line of Business HIM and Medicaid, section I.B and section II.B. Official Centene clinical policy PDF, published at ambetterhealth.com in the Ambetter Illinois policy-notifications folder (downloaded and read in full, all 9 pages). The current corporate copy of CP.PMN.298 was confirmed live at ambetterhealth.com but is published with its text converted to vector outlines, so it carries no extractable text and could not be read; the Illinois-hosted copy is the most recent readable version. Ambetter's own 2Q 2026 criteria-change summary lists what the later review altered, and the weight-management exclusion is not on that list. Cross-read against the Ambetter Arkansas member-news notice of November 21 2025 at ambetterhealth.com.. Verified August 15, 2026.

This is the pathway that survives the weight-management exclusion, and the policy is strict about which cardiovascular history qualifies. The six-month physician-directed weight loss program is a documentation requirement here even though weight loss is not the approved indication. For Illinois marketplace requests the policy footnotes that the diabetes step therapy does not apply as of January 1 2026 per Illinois HB 5395.

What the prior authorization needs:

• Age 18 or older
• Prescriber attestation that the member is currently receiving cardiovascular standard of care management
• Actively enrolled in a physician-directed weight loss program for at least 6 months, and continuing in it while on Wegovy
• Documentation of baseline body weight in kg
• Not prescribed with another semaglutide product or any other GLP-1 receptor agonist
• The requested dose follows the label escalation schedule, ending at 2.4 mg once weekly for the injection or 25 mg per day for the tablet

Policy CP.PMN.295. Source: Clinical Policy: Semaglutide (Wegovy), Reference Number CP.PMN.295, Last Review Date 05.26, section I.A Cardiovascular Event Prevention and section II.A Continued Therapy. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full). Verified August 15, 2026.

Wegovy injection carries an FDA indication for noncirrhotic MASH with moderate to advanced fibrosis, and Centene wrote a pathway for it. The policy accepts either a biopsy or a paired serum plus imaging workup, naming FIB-4, NAFLD fibrosis score and the enhanced liver fibrosis test as serum examples and transient elastography, magnetic resonance elastography and MRI-PDFF as imaging examples. The policy notes that continued FDA approval for this indication may depend on a confirmatory trial.

What the prior authorization needs:

• Age 18 or older
• Request is for Wegovy injection, not the tablet
• Prescribed by or in consultation with a hepatologist or gastroenterologist
• Stage F2 or F3 fibrosis confirmed by a liver biopsy within the last 3 years, or by both a serum-based assessment and an imaging-based assessment within the last 6 months
• Actively enrolled in a physician-directed weight loss program for at least 6 months and continuing in it
• Prescriber attestation of standard of care management for related conditions including type 2 diabetes, dyslipidemia and hypertension
• Not prescribed with Rezdiffra, another semaglutide product, or any other GLP-1 receptor agonist

Policy CP.PMN.295. Source: Clinical Policy: Semaglutide (Wegovy), Reference Number CP.PMN.295, Last Review Date 05.26, section I.C and section II.C Metabolic Dysfunction-Associated Steatohepatitis. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full). Verified August 15, 2026.

Sleep apnea is the one route to Zepbound on an Ambetter marketplace plan outside California. The PAP requirement is written as an either-or rather than a mandatory trial, so a member who cannot tolerate PAP is not shut out, but the request has to say which branch applies. Weight loss alone does not renew it. The file also needs a sleep measurement or a validated symptom score.

What the prior authorization needs:

• Age 18 or older
• No central or mixed sleep apnea
• Either a documented history of non-adherence to positive airway pressure therapy, or Zepbound prescribed alongside PAP therapy unless PAP is contraindicated or caused significant adverse effects
• Actively enrolled in a physician-directed weight loss program for at least 6 months and continuing in it
• Documentation of baseline body weight in kg
• Not prescribed with another tirzepatide product or any other GLP-1 receptor agonist
• Dose follows the label escalation schedule to a maximum of 15 mg once weekly, one pen or vial per week

Policy CP.PMN.298. Source: Clinical Policy: Tirzepatide (Zepbound), Reference Number CP.PMN.298, Effective Date 12.20.24, Last Review Date 02.25, section I.A and section II.A Obstructive Sleep Apnea. Official Centene clinical policy PDF, published at ambetterhealth.com (downloaded and read in full). The current corporate copy at ambetterhealth.com carries no extractable text because its text is published as vector outlines, so these thresholds are read from the most recent readable version. Ambetter's 2Q 2026 criteria-change summary records that the later review changed the diabetes-step wording, renamed the preferred liraglutide product, clarified that the continuation weight loss program must be physician directed, and added dosage forms; it records no change to the AHI, age or BMI thresholds.. Verified August 15, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.

California is where the Centene answer flips. The Ambetter From Health Net Drug List for 2026 answers its own question directly: "Are Weight loss drugs covered? Most plans do cover weight loss medications after prior authorization has been approved." It then lists the covered weight-loss medications, and Wegovy, Wegovy Tablets, Zepbound and liraglutide (Saxenda) are on that list alongside Contrave, Qsymia, phentermine and orlistat. The governing criteria come from Health Net of California's own policies rather than the Centene marketplace policies, and both carry a BMI table with a separate Marketplace row set at BMI 40 or higher. Both policies open with the same caution: check the member's benefits for coverage of weight loss drugs, some large groups have different BMI requirements, some PPO plans may not have coverage, and compounded medications and samples are excluded. The Zepbound policy adds a grandfathering rule, so a member already approved under a lower threshold keeps it unless therapy lapses for more than 90 days.

What the prior authorization needs:

• Active participation in a Health Net approved weight loss program such as Weight Watchers or Active&Fit, or a prescriber-recommended lifestyle plan, for at least 6 months before starting the drug
• Agreement to stay in that program during treatment
• Documentation of current height and body weight to calculate BMI within the last 30 days
• Not prescribed with another GLP-1 or GIP/GLP-1 receptor agonist
• For Zepbound, age 18 or older, planned follow-up visits, and a dose not exceeding 15 mg once weekly
• For Zepbound, a request for the pre-filled single-use pen requires the member to use the KwikPen formulation

Policy HNCA.CP.CPA.352 (Wegovy) and HNCA.CP.CPA.359 (Zepbound). Source: Health Net of California Clinical Policy: Semaglutide (Wegovy), Reference Number HNCA.CP.CPA.352, Last Review Date 03.26, Line of Business Commercial and HIM, section I.A Weight Management and its BMI table. Official Health Net of California clinical policy PDF published at healthnet.com (downloaded and read in full, 20 pages). Cross-read against Health Net of California Clinical Policy HNCA.CP.CPA.359 Tirzepatide (Zepbound), last review date 07.01.26, at the same domain, which carries the identical BMI table and the grandfathering rule. The covered-drug list and the prior-authorization statement were read from the California Ambetter From Health Net Drug List 2026 at healthnet.com.. Verified August 15, 2026.

The California sleep-apnea route sets a harder PAP test than the Centene marketplace policy does. Where the marketplace policy accepts a documented history of PAP non-adherence, Health Net wants either a documented failure while adherent, with adherence defined in hours and nights, or evidence that PAP was never an option. It also caps the dose at 10 mg weekly for sleep apnea against 15 mg for weight management, and it requires the sleep study to be recent rather than merely on file.

What the prior authorization needs:

• Age 18 or older
• No central or mixed sleep apnea
• Either continued OSA symptoms despite adherence to positive airway pressure therapy, where adherence means at least 4 hours per night on at least 70 percent of nights, or documentation that the member is not a candidate for PAP
• Active participation in a Health Net approved weight loss program or prescriber-recommended lifestyle plan for at least 6 months before starting, and continuing during treatment
• Documentation of baseline body weight within the last 30 days
• Dose does not exceed 10 mg once weekly
• A request for the pre-filled single-use pen requires the member to use the KwikPen formulation

Policy HNCA.CP.CPA.359. Source: Health Net of California Clinical Policy: Tirzepatide (Zepbound), Reference Number HNCA.CP.CPA.359, Effective Date 09.24, Last Review Date 07.01.26, Line of Business Commercial and HIM, section I.B Obstructive Sleep Apnea. Official Health Net of California clinical policy PDF published at healthnet.com (downloaded and read in full, 17 pages). Verified August 15, 2026.

We read six 2026 Ambetter formularies, all effective January 1 2026, covering Centene's largest marketplace states. None of them lists either drug on this page. That is consistent with the clinical policies but it does not prove the same thing. The formularies set out the limits of their own authority in the front matter: "the Formulary is not meant to be a complete list of the drugs covered under your prescription benefit", and "Specific prescription benefit plan designs may not cover certain products or categories, regardless of their appearance in this document." The practical consequence for an approved sleep-apnea or cardiovascular request is that it runs through the non-formulary prior-authorization route, which the documents describe as a 24-hour turnaround for urgent requests and 72 hours otherwise, unless state law is faster.

What the prior authorization needs:

• Wegovy, Zepbound, Saxenda and tirzepatide appear nowhere on the 2026 formularies for Florida, Texas, Georgia, North Carolina, Tennessee or New York
• The listed anti-obesity drugs on all six are phentermine hcl capsules and phendimetrazine tartrate tablets, both coded PA
• Ozempic, Rybelsus and Trulicity are listed for diabetes at Tier 2 with prior authorization and quantity limits
• Absence from the drug list is not by itself a coverage decision, because the formularies say they are not complete lists
• A drug approved through the non-formulary pathway is paid at Tier 3 under the documents' own tier key

Source: Ambetter from Sunshine Health 2026 Formulary, effective January 1 2026, document code AMB25-FL-C-00023, formulary introduction and the ADHD/anti-narcolepsy/anti-obesity/anorexiants section. Official payer formulary PDF (downloaded from ambetter.sunshinehealth.com and searched in full for every Wegovy, Zepbound, Saxenda, tirzepatide and semaglutide string). Cross-checked the same way against the 2026 Ambetter formularies for Texas (ambetter.superiorhealthplan.com), Georgia and Tennessee and North Carolina (ambetterhealth.com), and the Ambetter from Fidelis Care 2026 Qualified Health Plans formulary (fideliscare.org). All six return no match for either drug.. Verified August 15, 2026.